Compare Bristol-Myers Squibb Co (BMY) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Marqeta Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.48 (market cap $116.30B), while Marqeta Inc trades at $17.22 (market cap $1.70B). The key difference: Bristol-Myers Squibb Co is far larger — about 68.4× Marqeta Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| BMY | MQ | |
|---|---|---|
Market Cap | $116.30B | $1.70B |
Sector | Health | Technology |
52-Week High | $62.37 | $27.32 |
52-Week Low | $42.60 | $15.04 |
Enterprise Value | $152.24B | $999.94M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Marqeta (MQ) trades at $16.43, up 3.53% with a bullish technical signal. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025, with revenue growth from $507M in 2024 to $625M in 2025. A recent 1-for-4 reverse stock split took effect on July 1, 2026. Cash flow improved to a net positive $86M in 2025. Analyst consensus is a $19 price target with 32% buy ratings.
Outlook is cautiously optimistic given earnings volatility and high valuation multiples. Opportunities include European expansion and credit product growth, but risks involve thin net margins and potential fiduciary duty lawsuits. The stock's upside depends on sustained profitability and execution of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
